Cargando…
Characteristics and Outcomes of Recipients of Heart Transplant with Coronarvirus Disease 2019 Who Received Casirivimab Plus Imdevimab Infusion
PURPOSE: Heart transplant (HT) recipient are at increased risk of adverse outcomes following COVID-19 infection and may benefit from monoclonal antibody infusion to mitigate progression to clinically severe disease. The aim of this study is to describe the outcomes of HT patients who experienced mil...
Autores principales: | Gaine, M., Bae, D., Oh, D., Lotan, D., Atanda, A., Oren, D., Latif, F., Yuzefpolskaya, M., Habal, M., Griffin, J., Majure, D., Colombo, P., Jennings, D., Choe, J., Clerkin, K., Fried, J., Raikhelkar, J., Lee, S., Restaino, S., Sayer, G., Uriel, N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988630/ http://dx.doi.org/10.1016/j.healun.2022.01.1401 |
Ejemplares similares
-
LIGA ACADÊMICA DE HEMATOLOGIA NO CURSO DE MEDICINA: UM RELATO DE EXPERIÊNCIA DAS AÇÕES EM ENSINO A DIST NCIA (EAD) EM TEMPOS DA PANDEMIA DO COVID-19
por: Albuquerque, L.G., et al.
Publicado: (2020) -
Casirivimab/Imdevimab: First Approval
por: Deeks, Emma D.
Publicado: (2021) -
Casirivimab and imdevimab for COVID-19
Publicado: (2022) -
Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19
por: Somersan-Karakaya, Selin, et al.
Publicado: (2022) -
Casirivimab/imdevimab: Lack of efficacy: case report
Publicado: (2022)